atory multisystem disease of chronic infant skin and neurological syndrome (CINCA).
Muckle-Wells Syndrome (MWS).
Familial cold autoinflammatory syndrome (FCAS).
Still disease, including (AOSD) cytokines are produced by communication between our body protein coordinating communities and help control cellular activity in juvenile idiopathic arthritis (AIJS) and disease onset still. In RA, CAPS and Still disease, the body produces an excess of cytokines called interleukin-1. This can cause inflammation and cause harmful effects of disease symptoms. Usually, the body produces a protein that blocks the harmful effects of interleukin-1. The active substance in Kineret is anakinra, which acts in a similar manner to the natural protein that blocks interleukin-1. Anakinra is obtained by recombinant DNA technology using E. coli microorganisms.
In AR, Kineret is used to treat the symptoms and signs of an adult (over 18 years of age) disease and is used in combination with another drug called methotrexate. Kineret is suitable for patients with rheumatoid arthritis who are not responding to methotrexate alone.
In CAPS, Kineret is used to treat inflammatory signs and symptoms associated with the disease, such as rash, joint pain, fever, headache and fatigue, and age in adults and children (8 months).
In Still's disease, Kineret is used to treat the symptoms and signs of inflammation associated with the disease, such as rashes, joint pain and fever. |
